Supporting Information

One-Pot Preparation of Cetylpyridinium Chloride-Containing Nanoparticles for Biofilm Eradication

Alexander Brezhnev,[‡]^a Fung-Kit Tang,[‡]^b Chak-Shing Kwan,^b Mohammed S. Basabrain,^a James Kit Hon Tsoi,^c Jukka P. Matinlinna,^{cd} Prasanna Neelakantan^{*a} and Ken Cham-Fai Leung^{*b}

^a Restorative Dental Sciences, Discipline of Endodontology, Faculty of Dentistry, The University of Hong Kong, Hong Kong Island, Hong Kong SAR, P. R. China

^b Department of Chemistry, State Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, P. R. China

^c Applied Oral Sciences and Community Dental Care, Dental Materials Science, Faculty of Dentistry, The University of Hong Kong, Hong Kong Island, Hong Kong SAR, P. R. China

^d Division of Dentistry, The University of Manchester, Manchester, M13 9PL, United Kingdom

*E-mails: cfleung@hkbu.edu.hk (K.C.-F.L.); prasanna@hku.hk (P.N.)

[‡] These authors contributed equally to this work.



Figure S1. Additional transmission electron microscopic (TEM) images of CPC-MSN at different magnifications.



Figure S2. Additional scanning electron microscopic (SEM) images of **CPC-MSN** at different magnifications.





Figure S3. Size distribution of **CPC-MSN** (estimated from TEM images). (a) Length; (b) Width. Number of particles measured = 145.



Figure S4. (a) Diffractogram of **CPC-MSN** through Fast Fourier Transform (FFT) analysis. (b) Enlarged TEM image showing the channels. Scale bar = 20 nm.



Figure S5. Small-angle X-ray powder diffraction (SAXRD) pattern of CPC-MSN.



Figure S6. Wide-angle X-ray powder diffraction (WAXRD) pattern of CPC-MSN.



Figure S7. UV-Vis spectrum of 1 mM cetylpyridinium chloride (CPC) in H_2O . Molar extinction coefficient was estimated as 6573 M^{-1} cm⁻¹ at 260 nm.



Figure S8. The cell viability of NIH/3T3 mouse fibroblasts after 24 h treatment with CPC-MSN (loaded with CPC drug) and **free-MSN** (drug-free form) was assessed using CCK-8 by measuring the absorbance of the supernatant at 450 nm wavelength. Three independent experiments in triplicate were performed.



Figure S9. The bright-field cell images (NIH/3T3 cells) after treatment with **CPC-MSN** (loaded with CPC drug) $8-32 \ \mu g/mL$ and **free-MSN** (drug-free form) $8-256 \ \mu g/mL$. Magnification ×4, scale bar = 200 μm .



Figure S10. Additional scanning electron microscopic (SEM) images for dentinal tubule penetration by **CPC-MSN**. Arrows pointing to **CPC-MSN** inside dentinal tubules. Scale of (a) and (b) = $10 \mu m$.

 Table S1. NMR characterization of CPC drug used in this study:

$^{1}HNMR$	¹ H NMR (400 MHz, CDCl ₃ , 298K) δ 9.47 (d, <i>J</i> = 5.6 Hz, 2H), 8.48 (t,
	J = 7.8 Hz, 1H), 8.12 (t, $J = 7.1$ Hz, 2H), 5.00 (t, $J = 7.4$ Hz, 2H), 2.05
	-1.96 (m, 2H), $1.38 - 1.15$ (m, 26H), 0.86 (t, $J = 6.9$ Hz, 3H).
¹³ C NMR	¹³ C NMR (101 MHz, CDCl ₃ , 298K) δ 145.27, 145.16, 128.56, 62.08,
	32.03, 31.94, 29.70, 29.57, 29.40, 29.15, 26.15, 22.71, 14.15.



Figure S11. ¹H NMR spectrum (400 MHz, CDCl₃, 298 K) of pristine CPC used.



Figure S12. ¹³C{¹H} NMR spectrum (101 MHz, CDCl₃, 298 K) of pristine CPC used.